{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:50:43Z","timestamp":1792716643612,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interaction of very late antigen-4 (VLA-4) with its ligand vascular cell adhesion molecule-1 (VCAM-1) is required for central nervous system (CNS) migration of encephalitogenic T cells in relapsing experimental autoimmune encephalomyelitis (R-EAE). Anti-VLA-4 monoclonal antibody (mAb) treatment prior to EAE onset inhibits disease induction; however, treatment initiated after the appearance of clinical symptoms increases relapse rates, augments Th1 responses, and enhances epitope spreading perhaps due to the activation of costimulatory signals. To negate the potential costimulatory activity of intact anti-VLA-4, we examined the ability of BIO 5192, a small-molecule VLA-4 antagonist, to regulate active proteolipid protein 139-151 (PLP139-151)-induced R-EAE. BIO 5192 administered one week after peptide priming (ie, before clinical disease onset) delayed the clinical disease onset but led to severe disease exacerbation upon treatment removal. BIO 5192 treatment initiated during disease remission moderately enhanced clinical disease while mice were on treatment and also resulted in posttreatment exacerbation. Interestingly, BIO 5192 treatment begun at the peak of acute disease accelerated entrance into disease remission and inhibited relapses, but treatment removal again exacerbated disease. Enhanced disease was caused by the release of encephalitogenic cells from the periphery and the rapid accumulation of T cells in the CNS. Collectively, these results further demonstrate the complexity of VLA-4\/VCAM interactions, particularly in a relapsing-remitting autoimmune disease. (Blood. 2003;102:4464-4471)<\/jats:p>","DOI":"10.1182\/blood-2003-03-0974","type":"journal-article","created":{"date-parts":[[2003,8,26]],"date-time":"2003-08-26T00:48:58Z","timestamp":1061858938000},"page":"4464-4471","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE"],"prefix":"10.1182","volume":"102","author":[{"given":"Bradley E.","family":"Theien","sequence":"first","affiliation":[{"name":"From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Vanderlugt","sequence":"additional","affiliation":[{"name":"From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Nickerson-Nutter","sequence":"additional","affiliation":[{"name":"From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cornebise","sequence":"additional","affiliation":[{"name":"From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Scott","sequence":"additional","affiliation":[{"name":"From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Perper","sequence":"additional","affiliation":[{"name":"From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Whalley","sequence":"additional","affiliation":[{"name":"From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Miller","sequence":"additional","affiliation":[{"name":"From the Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL; and Biogen Inc, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021221512729400_REF1","unstructured":"Brown AM, McFarlin DE. Relapsing experimental allergic encephalomyelitis in the SJL\/J mouse. Lab Invest. 1981;45: 278-284."},{"key":"2020021221512729400_REF2","doi-asserted-by":"crossref","unstructured":"McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Miller SD. Induction of active and adoptive chronic-relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol. 1992;38: 229-240.","DOI":"10.1016\/0165-5728(92)90016-E"},{"key":"2020021221512729400_REF3","doi-asserted-by":"crossref","unstructured":"McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med. 1995;182: 75-85.","DOI":"10.1084\/jem.182.1.75"},{"key":"2020021221512729400_REF4","doi-asserted-by":"crossref","unstructured":"Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med. 1996;183: 1777-1788.","DOI":"10.1084\/jem.183.4.1777"},{"key":"2020021221512729400_REF5","doi-asserted-by":"crossref","unstructured":"Vanderlugt CL, Begolka WS, Neville KL, et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev. 1998;164: 63-72.","DOI":"10.1111\/j.1600-065X.1998.tb01208.x"},{"key":"2020021221512729400_REF6","doi-asserted-by":"crossref","unstructured":"Vanderlugt CL, Eagar TN, Neville KL, et al. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol. 2000;164: 670-678.","DOI":"10.4049\/jimmunol.164.2.670"},{"key":"2020021221512729400_REF7","doi-asserted-by":"crossref","unstructured":"Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against \u03b14\u03b21 integrin. Nature. 1992;356: 63-66.","DOI":"10.1038\/356063a0"},{"key":"2020021221512729400_","doi-asserted-by":"crossref","unstructured":"Kuchroo VK, Sobel RA, Laning JC, et al. Experimental allergic encephalomyelitis mediated by cloned T cells specific for a synthetic peptide of myelin proteolipid protein: fine specificity and T cell receptor V-beta usage. J Immunol. 1992;148: 3776-3782.","DOI":"10.4049\/jimmunol.148.12.3776"},{"key":"2020021221512729400_REF9","doi-asserted-by":"crossref","unstructured":"Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993;177: 57-68.","DOI":"10.1084\/jem.177.1.57"},{"key":"2020021221512729400_REF10","doi-asserted-by":"crossref","unstructured":"Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A. 1999;96: 6896-6901.","DOI":"10.1073\/pnas.96.12.6896"},{"key":"2020021221512729400_REF11","doi-asserted-by":"crossref","unstructured":"Avdalovic M, Fong D, Formby B. Adhesion and costimulation of proliferative responses of human gamma delta T cells by interaction of VLA-4 and VLA-5 with fibronectin. Immunol Lett. 1993;35: 101-108.","DOI":"10.1016\/0165-2478(93)90077-F"},{"key":"2020021221512729400_","doi-asserted-by":"crossref","unstructured":"Sato T, Tachibana K, Nojima Y, D'Avirro N, Morimoto C. Role of the VLA-4 molecule in T cell costimulation: identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J Immunol. 1995;155: 2938-2947.","DOI":"10.4049\/jimmunol.155.6.2938"},{"key":"2020021221512729400_","doi-asserted-by":"crossref","unstructured":"Shimizu Y, Van Seventer GA, Horgan KJ, Shaw S. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol. 1990;145: 59-67.","DOI":"10.4049\/jimmunol.145.1.59"},{"key":"2020021221512729400_REF14","doi-asserted-by":"crossref","unstructured":"Van Seventer GA, Newman W, Shimizu Y, et al. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J Exp Med. 1991;174: 901-913.","DOI":"10.1084\/jem.174.4.901"},{"key":"2020021221512729400_REF15","doi-asserted-by":"crossref","unstructured":"Theien BE, Vanderlugt CL, Eagar TN, et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest. 2001;107: 995-1006.","DOI":"10.1172\/JCI11717"},{"key":"2020021221512729400_REF16","doi-asserted-by":"crossref","unstructured":"Leone DR, Giza K, Gill A, et al. An assessment of the mechanistic differences between two integrin a4b1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2003;305: 1150-1162.","DOI":"10.1124\/jpet.102.047332"},{"key":"2020021221512729400_REF17","doi-asserted-by":"crossref","unstructured":"Kuchroo VK, Martin CA, Greer JM, et al. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental autoimmune encephalomyelitis. J Immunol. 1993;151: 4371-4382.","DOI":"10.4049\/jimmunol.151.8.4371"},{"key":"2020021221512729400_REF18","doi-asserted-by":"crossref","unstructured":"Haworth D, Rees A, Alcock PJ, et al. Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion. Br J Pharmacol. 1999;126: 1751-1760.","DOI":"10.1038\/sj.bjp.0702511"},{"key":"2020021221512729400_REF19","doi-asserted-by":"crossref","unstructured":"Abraham WM, Ahmed A, Sabater JR, et al. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med. 1999;159: 1205-1214.","DOI":"10.1164\/ajrccm.159.4.9806002"},{"key":"2020021221512729400_REF20","doi-asserted-by":"crossref","unstructured":"Lin KC, Ateeq HS, Hsiung SH, et al. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J Med Chem. 1999;42: 920-934.","DOI":"10.1021\/jm980673g"},{"key":"2020021221512729400_REF21","doi-asserted-by":"crossref","unstructured":"Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348: 15-23.","DOI":"10.1056\/NEJMoa020696"},{"key":"2020021221512729400_REF22","doi-asserted-by":"crossref","unstructured":"Kent SJ, Karlik SJ, Rice GP, Horner HC. A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging. 1995;5: 535-540.","DOI":"10.1002\/jmri.1880050510"},{"key":"2020021221512729400_REF23","doi-asserted-by":"crossref","unstructured":"Keszthelyi E, Karlik S, Hyduk S, et al. Evidence for a prolonged role of alpha 4 integrin throughout active experimental allergic encephalomyelitis. Neurology. 1996;47: 1053-1059.","DOI":"10.1212\/WNL.47.4.1053"},{"key":"2020021221512729400_REF24","doi-asserted-by":"crossref","unstructured":"McIntyre BW, Woodside DG, Caruso DA, et al. Regulation of human T lymphocyte coactivation with an alpha4 integrin antagonist peptide. J Immunol. 1997;158: 4180-4186.","DOI":"10.4049\/jimmunol.158.9.4180"},{"key":"2020021221512729400_REF25","doi-asserted-by":"crossref","unstructured":"Chen LL, Whitty A, Lobb RR, Adams SP, Pepinsky RB. Multiple activation states of integrin alpha4beta1 detected through their different affinities for a small molecule ligand. J Biol Chem. 1999;274: 13167-13175.","DOI":"10.1074\/jbc.274.19.13167"},{"key":"2020021221512729400_REF26","doi-asserted-by":"crossref","unstructured":"Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting edge: CD4(+)CD25(+) regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol. 2002;169: 4712-4716.","DOI":"10.4049\/jimmunol.169.9.4712"},{"key":"2020021221512729400_REF27","doi-asserted-by":"crossref","unstructured":"Piraino PS, Yednock TA, Freedman SB, et al. Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of \u03b14 integrin. J Neuroimmunol. 2002;131: 147-159.","DOI":"10.1016\/S0165-5728(02)00273-4"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4464\/1693888\/h82403004464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4464\/1693888\/h82403004464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T20:56:07Z","timestamp":1682542567000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/13\/4464\/17475\/Differential-effects-of-treatment-with-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,15]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-03-0974","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,15]]}}}